←Back to Expert Scholars
Translational Medicine / 转化医学KRAS Combination Therapy
Jeffrey Rosenblatt
MD
🏢Mirati Therapeutics🌐USA
Clinical Investigator
22
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jeffrey Rosenblatt supports clinical development of adagrasib and combination strategies with cetuximab for KRAS G12C mutant colorectal cancer. His work helped shape the KRYSTAL program and subsequent combination trials. He contributes to translating KRAS biology into therapy.
Share:
🧪Research Fields 研究领域
KRAS G12C
adagrasib
clinical development
combination therapy
colorectal cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jeffrey Rosenblatt 的研究动态
Follow Jeffrey Rosenblatt's research updates
留下邮箱，当我们发布与 Jeffrey Rosenblatt（Mirati Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment